[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364033-105":59,"doc-detail-364033-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exome-based-cancer-driver-gene-comprehensive-testing-can-provide-a-genetic-diagnosis-for-individuals-with-triple-negative-breast-cancer-research-article","Exome-based cancer driver gene comprehensive testing can provide a genetic diagnosis for individuals with triple-negative breast cancer - Research Article","","Triple-negative breast cancer (TNBC) is marked by aggressive behavior, high tumor heterogeneity, and elevated risk of recurrence and early metastasis, making effective treatment difficult. This study validates whole-exome sequencing (WES) with variant prioritization in cancer susceptibility genes tied to hereditary cancer predisposition in TNBC patients. A reproducible bioinformatic pipeline is technically validated using a gold-standard cohort with confirmed hereditary cancer syndromes. A comprehensive cancer gene panel is consolidated, variants are determined, and pathogenic germline findings in ATM, RAD51D, and BRCA1 are reported, demonstrating reliable hereditary cancer diagnosis from exome data for TNBC and other suspected cases.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exome-based-cancer-driver-gene-comprehensive-testing-can-provide-a-genetic-diagnosis-for-individuals-with-triple-negative-breast-cancer-research-article/364033/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exome-based-cancer-driver-gene-comprehensive-testing-can-provide-a-genetic-diagnosis-for-individuals-with-triple-negative-breast-cancer-research-article/364033.png","ImageObject",300,407,{"name":92,"@type":93},"mieayamfan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study on TNBC?","Question",{"text":112,"@type":113},"To validate whole-exome sequencing and variant prioritization in cancer susceptibility genes associated with hereditary cancer predisposition in TNBC patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the bioinformatic pipeline evaluated?",{"text":117,"@type":113},"By developing a reproducible pipeline and performing technical validation in a validation cohort composed of individuals with diverse tumors and previously confirmed hereditary cancer syndrome diagnoses.",{"name":119,"@type":110,"acceptedAnswer":120},"Which pathogenic germline variants were identified?",{"text":121,"@type":113},"Three pathogenic germline variants were identified in ATM, RAD51D, and BRCA1, linked to the DNA repair pathway involving homologous recombination.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364033,1790181575,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","OPEN ACCESS  \nCitation: Alzate D, Sánchez AY, Pacheco Y, Isaza Ruget M, Sánchez R, Castillo C, et al.(2026) Exome-based cancer driver gene comprehensive testing can provide a genetic diagnosis for individuals with triple-negative breast cancer. PLoS One 21(8): e0356762 .  \n[https://doi.org/10.1371/journal.pone.0356762](https://doi.org/10.1371/journal.pone.0356762)[ ](https://doi.org/10.1371/journal.pone.0356762)Editor: Klaus Brusgaard, Odense University Hospital, DENMARK  \nReceived: November 24, 2025  \nAccepted: August 7, 2026  \nPublished: August 24, 2026  \nCopyright: © 2026 Alzate et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the paper and its Supporting  Information files.  \nFunding: This work was supported by grants from the Colombian Ministry of Science, Technology, and Innovation (MinCiencias),  \nRESEARCH ARTICLE  \nExome-based cancer driver gene comprehensive testing can provide a genetic diagnosis for individuals with triple-negative breast cancer  \nDaniel Alzate1,2, Angel Yobany Sánchez3, Yovana Pacheco4, Mario Isaza Ruget4, Ramiro Sánchez5, Carolina Castillo5, Carlos A. Parra-López1,6*  \n1 Immunology and Translational Medicine Group, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia, 2 PhD Programme in Oncology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia, 3 Department of Pathology, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia, 4 Clinical Pathology Research Group (INPAC), Research Unit, Fundación Universitaria Sanitas, Bogotá, Colombia, 5 Clínica del Seno, Bogotá, Colombia, 6 Microbiology Department, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia  \n* [caparral@unal.edu.co](caparral@unal.edu.co)  \nAbstract  \nTriple-negative breast cancer (TNBC) is characterized by aggressive behaviour, high tumor heterogeneity, and an increased likelihood of recurrence and early metastasis. These factors hinder successful treatment. Genetic diagnosis enables personalized clinical recommendations and treatment options. The objective of this study was to validate whole-exome sequencing (WES) and variant prioritization in cancer susceptibility genes (CSG) associated with hereditary cancer (HC) predisposition in TNBC patients (n = 24) . We present the development of a reproducible bioinformatic pipeline and its technical validation in a validation cohort (n = 25) . This cohort comprised individuals with diverse primary tumors who had a previously confirmed molecular diagnosis of a hereditary cancer syndrome, serving as gold-standard cases to assess the pipeline’s analytical accuracy. We consolidated a comprehensive panel of cancer genes and determined all variants in the TNBC discovery cohort (12 .5% of patients), identifying three pathogenic germline variants (gPV) in ATM, RAD51D, and BRCA1 . These genes are involved in the molecular pathway of DNA repair by homologous recombination (HRD) . Our results demonstrate that the developed bioinformatic pipeline provides reliable genetic diagnosis of cancer predisposition syndromes from exome data, applicable not only to TNBC patients but also to individuals with any cancer suspected of having a hereditary component.  \nIntroduction  \nTriple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancers and is generally very aggressive, with more frequent distant spread, high tumor heterogeneity, higher recurrence, and earlier metastasis, all of which hinder  \nPLOS One | [https://doi.org/10.1371/journal.pone.0356762](https://doi.org/10.1371/journal.pone.0356762) August 24, 2026 1 / 12  \nProgram 92191, Project 92268, Contract No. 800-2023, and by institutional funding from Fundación Salud de los Andes (Bogotá, Colombia). Addit","cbCaiuaRuFmXcg4a","https://ap.wps.com/l/cbCaiuaRuFmXcg4a","pdf",756359,12,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main goal of the study on TNBC?\",\"answer\":\"To validate whole-exome sequencing and variant prioritization in cancer susceptibility genes associated with hereditary cancer predisposition in TNBC patients.\"},{\"question\":\"How was the bioinformatic pipeline evaluated?\",\"answer\":\"By developing a reproducible pipeline and performing technical validation in a validation cohort composed of individuals with diverse tumors and previously confirmed hereditary cancer syndrome diagnoses.\"},{\"question\":\"Which pathogenic germline variants were identified?\",\"answer\":\"Three pathogenic germline variants were identified in ATM, RAD51D, and BRCA1, linked to the DNA repair pathway involving homologous recombination.\"}]","Exome-based cancer driver gene comprehensive testing can provide a genetic diagnosis for individuals with triple-negative breast cancer - Research Article | PDF",1790155219,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fae05b96277a3b0510a31cabb9e455d5.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2632963b207c9bb6ea298cfb1d79a950.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c1fcb6884831e6c9db4ef30703363c6.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5ad1f0e08a6818e69e8859794c5231d.webp",980,1268]